Spruce Biosciences (SPRB) Competitors $8.20 -0.30 (-3.53%) As of 08/22/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. PMN, DARE, AYTU, GDTC, ASBP, CMMB, COCP, SYBX, MTEX, and PULMShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Promis Neurosciences (PMN), Dare Bioscience (DARE), Aytu BioPharma (AYTU), CytoMed Therapeutics (GDTC), Aspire Biopharma (ASBP), Chemomab Therapeutics (CMMB), Cocrystal Pharma (COCP), Synlogic (SYBX), Mannatech (MTEX), and Pulmatrix (PULM). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors Promis Neurosciences Dare Bioscience Aytu BioPharma CytoMed Therapeutics Aspire Biopharma Chemomab Therapeutics Cocrystal Pharma Synlogic Mannatech Pulmatrix Promis Neurosciences (NASDAQ:PMN) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends. Do insiders & institutionals have more ownership in PMN or SPRB? 50.1% of Promis Neurosciences shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 6.1% of Promis Neurosciences shares are held by company insiders. Comparatively, 6.9% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is PMN or SPRB more profitable? Promis Neurosciences has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Promis Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Promis NeurosciencesN/A -266.69% -131.59% Spruce Biosciences -555.23%-62.10%-47.49% Which has higher valuation & earnings, PMN or SPRB? Promis Neurosciences has higher earnings, but lower revenue than Spruce Biosciences. Promis Neurosciences is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPromis NeurosciencesN/AN/A$2.78M-$0.21-2.55Spruce Biosciences$4.91M0.94-$47.92M-$99.25-0.08 Does the media favor PMN or SPRB? In the previous week, Spruce Biosciences had 2 more articles in the media than Promis Neurosciences. MarketBeat recorded 2 mentions for Spruce Biosciences and 0 mentions for Promis Neurosciences. Spruce Biosciences' average media sentiment score of 0.42 beat Promis Neurosciences' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Promis Neurosciences Neutral Spruce Biosciences Neutral Do analysts recommend PMN or SPRB? Promis Neurosciences presently has a consensus target price of $4.33, suggesting a potential upside of 708.61%. Spruce Biosciences has a consensus target price of $131.25, suggesting a potential upside of 1,500.61%. Given Spruce Biosciences' higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than Promis Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Promis Neurosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, PMN or SPRB? Promis Neurosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.43, indicating that its share price is 143% more volatile than the S&P 500. SummarySpruce Biosciences beats Promis Neurosciences on 9 of the 15 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.61M$834.78M$5.75B$9.62BDividend YieldN/A4.84%4.40%4.10%P/E Ratio-8.721.1831.3026.05Price / Sales0.9426.35432.98193.75Price / CashN/A19.5637.7358.48Price / Book4.366.649.536.61Net Income-$47.92M-$4.94M$3.26B$265.65M7 Day Performance-8.99%1.85%2.13%2.02%1 Month Performance-11.47%2.72%2.80%-0.31%1 Year Performance-77.10%10.97%30.68%19.06% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.3394 of 5 stars$8.20-3.5%$131.25+1,500.6%-75.2%$4.61M$4.91M-8.7220Gap DownPMNPromis Neurosciences2.4076 of 5 stars$0.62flat$4.33+602.3%-57.1%$20.17MN/A-2.945DAREDare Bioscience2.5307 of 5 stars$2.11-4.1%$12.00+468.7%-38.0%$19.87M-$17.70K-0.9930Analyst RevisionAYTUAytu BioPharma3.1359 of 5 stars$2.20-0.5%$10.00+354.5%-10.9%$19.84M$81.66M-3.06160Gap DownGDTCCytoMed Therapeutics2.2854 of 5 stars$1.78-1.4%$5.00+181.7%+15.6%$19.69M$69.50K0.00N/APositive NewsShort Interest ↓ASBPAspire BiopharmaN/A$0.59+64.3%N/AN/A$17.78MN/A0.00N/AGap DownHigh Trading VolumeCMMBChemomab Therapeutics3.4939 of 5 stars$0.94+1.1%$8.50+804.3%-27.0%$17.54MN/A-1.5920News CoverageShort Interest ↓Analyst RevisionCOCPCocrystal Pharma2.8896 of 5 stars$1.56-8.0%$6.00+284.6%-17.2%$17.39MN/A-1.2610News CoveragePositive NewsAnalyst RevisionSYBXSynlogicN/A$1.44-3.0%N/A-3.3%$17.32MN/A-0.5780Short Interest ↑Gap UpMTEXMannatech0.2781 of 5 stars$8.53-6.3%N/A+18.8%$17.30M$112.98M-4.18250Gap DownPULMPulmatrix0.417 of 5 stars$4.71flatN/A+138.5%$17.19M$369K-2.1720Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Promis Neurosciences Competitors Dare Bioscience Competitors Aytu BioPharma Competitors CytoMed Therapeutics Competitors Aspire Biopharma Competitors Chemomab Therapeutics Competitors Cocrystal Pharma Competitors Synlogic Competitors Mannatech Competitors Pulmatrix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access